1442. Pneumonia Hospitalizations Averted with 13-valent Pneumococcal Conjugate Vaccination of Adults Aged 18-64 Years with Diabetes in The United States
Session: Poster Abstract Session: Pneumococcal Vaccines
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • IDWeerk_diabetes_2018v10f.pdf (125.2 kB)
  • Background: Diabetes, a prevalent chronic condition in younger adults, increases the risk of pneumonia. The incidence of pneumonia hospitalization among adults aged <65 years with diabetes is comparable to that of the overall population aged ≥65 years. While 13-valent conjugate pneumococcal vaccination (PCV13) is routinely recommended for adults aged ≥65 years, it has not been recommended for younger adults with diabetes. We modeled the potential impact of PCV13 use in this population.

    Methods: We estimated the cumulative number of pneumonia hospitalizations and hospital days potentially averted with PCV13 use in adults aged <65 years with diabetes over five years in the United States. Model inputs are summarized in Table 1. We ran multiple scenarios depending on a number of vaccine efficacy/effectiveness (VE) estimates. We estimated the number of hospitalizations averted as the product of i) the size of the target population, ii) the incidence of all-cause CAP, iii) the proportion of CAP that is PCV13 type, iv) PCV13 effectiveness, and v) the duration of protection for PCV13 over a five-year time horizon. Number-needed-to-vaccinate (NNV) for each scenario was also assessed.

    Results: Roughly 15 million adults aged <65 years have diabetes in the United States, accounting for about 250,000 pneumonia hospitalizations annually. Based on published, US estimates of pneumonia incidence and PCV13 etiology, PCV13 vaccination in this population could avert 24,638 to 44,506 hospitalizations and 206,955 to 373,854 hospital days over a 5-year period. NNV to avert one hospitalization and one hospital day were 344 to 622 and 41 to 74, respectively.

    Conclusion: PCV13 vaccination of younger adults with diabetes could reduce a substantial number of pneumonia hospitalizations. NNV are comparable to those for adults aged ≥65 years, for whom PCV13 is currently recommended.

    Jose Suaya, MD, PhD1, Bradford D. Gessner, MD2, Erica Chilson, PharmD3, Jelena Vojicic, MD4, David L. Swerdlow, MD5, Raúl E. Isturiz, MD6 and John M. McLaughlin, PhD6, (1)Pneumococcal Vaccines, WW Medicines Development & Scientific Affairs, Pfizer Inc, New York, NY, (2)Pfizer Inc., Collegeville, PA, (3)Pfizer Inc, Collegeville, PA, (4)Pfizer Canada Inc., Kirkland, QC, Canada, (5)Mdsca, Pfizer Vaccines, Collegeville, PA, (6)Pfizer Vaccines, Collegeville, PA

    Disclosures:

    J. Suaya, Pfizer Inc.: Employee and Shareholder , Salary .

    B. D. Gessner, Pfizer Inc.: Employee and Shareholder , Salary .

    E. Chilson, Pfizer Inc: Employee and Shareholder , Salary .

    J. Vojicic, Pfizer: Employee and Shareholder , Benefits and stock and Salary .

    D. L. Swerdlow, Pfizer Inc: Employee and Shareholder , Salary .

    R. E. Isturiz, Pfizer: Employee and Shareholder , Benefits and stock and Salary .

    J. M. McLaughlin, Pfizer: Employee , Salary .

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.